Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants orphan drug status to anticancer product MDX-1097

June 30, 2011

EpiCept receives initial responses from FDA regarding SPA application for Ceplene in AML

June 30, 2011

Cixutumumab monotherapy is not beneficial in phase II hepatocellular carcinoma trial

June 30, 2011

Apeiron Biologics enters research alliance for neuroblastoma therapy CH-14.18

June 29, 2011

Amgen obtains positive CHMP opinion on Vectibix after reexamination

June 29, 2011

MORAb-004 is active in first-in-human study

June 29, 2011

Genmab shelves development activity for zalutumumab

June 28, 2011

TriMix-DC vaccine is safe and immunogenic in phase I trial in pretreated melanoma

June 23, 2011

GC-33 is safe in hepatocellular carcinoma in first-in-human study

June 23, 2011

Cel-Sci's anticancer drug Multikine lowers cholesterol in phase II trials

June 23, 2011

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...